Group 1 - The core viewpoint of the article is that Pacific Securities has issued a buy rating for Xiangsheng Medical (688358.SH) based on several positive factors [1] - The implementation of SonoAI is expected to reshape the diagnostic and treatment chain [1] - The company is increasing its investment in scanning robots to enhance breast cancer screening efforts [1] - The gross profit margin remains stable, although there is a slight increase in expenses [1] Group 2 - There are risks associated with a slowdown in bidding processes, risks from centralized procurement of equipment, and the potential for new business development to underperform expectations [1]